Baseline Urinary PGE-M Is a Prognostic and Predictive Marker for Cox-2 Inhibition in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): CALGB 30801 (Alliance)

Conclusions: WBRT with concurrent and maintenance icotinib (125 mg tid-375 mg tid) were tolerable and efficient in EGFR-mutated NSCLC patients with brain metastases. WBRT might not increase penetration rate of icotinib, and there were the highest CSF concentration and penetration rate at dose of 375 mg tid. Within 20 weeks of treatment, there was no neurocognitive function deterioration observed in this trail. Author Disclosure: L. Zhou: L. Funding Other; Research funding of present study was from Zhejiang Beta Pharma Inc. J. He: L. Funding Other; Research funding of present study was from Zhejiang Beta Pharma Inc. W. Xiong: L. Funding Other; Research funding of present study was from Zhejiang Beta Pharma Inc. Q. Yu: None. J. Xiang: None. M. Liang: None. J. Xue: None. Y. Liu: None. Z. Ding: None. Y. Gong: None. M. Huang: None. J. Zhu: None. L. Li: None. Y. Wang: None. M. Hou: None. L. Ren: None. Y. Lu: L. Funding Other; Research funding of present study was from Zhejiang Beta Pharma Inc.